People whose blood shows signs of inflammation are more likely to later develop Alzheimer's disease than people with no signs of inflammation, according to a study published in the May 29, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology.
The study, which is part of the larger Framingham Heart Study, involved 691 healthy people with an average age of 79. Blood tests determined whether the participants had signs of inflammation. Then the participants were followed for an average of seven years. During that time, 44 of the participants developed Alzheimer's disease.
The participants' blood was tested for levels of cytokines, which are protein messengers that trigger inflammation. Those with the highest amount of cytokines in their blood were more than twice as likely to develop Alzheimer's disease as those with the lowest amount of cytokines. A total of 28 percent of the women and 30 percent of the men had high levels of cytokines, yet they made up 42 percent of the cases of Alzheimer's disease.
"These results provide further evidence that inflammation plays a role in the development of Alzheimer's disease," said study author Zaldy Tan, MD, MPH, of Harvard Medical School in Boston. "The production of these cytokines may be a marker of future risk of Alzheimer's disease."
Source: American Academy of Neurology
Related stories:
Scientists Seek to Block Progression of Alzheimer’s Disease with Novel Medication that Targets the Source
(PhysOrg.com) -- Researchers at the University of California, San Diego Shiley-Marcos Alzheimer’s Research Center (ADRC) are conducting studies on an experimental medication to block nerve damage and inflammation in the brain that can lead to progressive memory loss and behavioral changes in people with Alzheimer’s disease. While current Alzheimer’s disease therapies focus on improving symptoms, this study aims to attack the root of the disease progression. Nationwide, 400 volunteers with mild to moderate Alzheimer’s disease are needed to further test this new approach.
Memory loss linked to common sleep disorder
For the first time, UCLA researchers have discovered that people with sleep apnea show tissue loss in brain regions that help store memory. Reported in the June 27 edition of the journal
Neuroscience Letters, the findings emphasize the importance of early detection of the disorder, which afflicts an estimated 20 million Americans.
Plant flavonoid found to reduce inflammatory response in the brain
Researchers at the University of Illinois report this week that a plant compound found in abundance in celery and green peppers can disrupt a key component of the inflammatory response in the brain. The findings have implications for research on aging and diseases such as Alzheimer’s and multiple sclerosis.
Scientists discover compound that could lead to new blood pressure drugs
University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and — in a remarkable finding — prevents damage to the heart and kidneys in rats with persistent hypertension.
Study links diabetes and Alzheimer's disease
Diabetic individuals have a significantly higher risk of developing Alzheimer’s disease but the molecular connection between the two remains unexplained. Now, researchers at the Salk Institute for Biological Studies identified the probable molecular basis for the diabetes – Alzheimer’s interaction.
Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimer's disease
Targeted immune suppression using human umbilical cord blood cells may improve the pathology associated with Alzheimer’s disease, a new study in a mouse model of this currently untreatable neurodegenerative condition reports. The study, led by researchers at the University of South Florida, is published online in the peer-reviewed journal
Stem Cells and Development.
China's biotech industry: An Asian dragon is growing
Backed by a government intent on promoting innovation and fuelled by the “brain gain” of talented scientists and entrepreneurs returning from abroad, China’s health biotech industry only needs a more favourable investment climate to emerge as a global force in the production of therapies and medicines – both new and low-cost generics – experts say in a new study.
International scientists tackle obstacles to treating brain disorders
A research team led by scientists at the University of Minnesota Medical School and Oregon Health & Science University have outlined the challenges and made suggestions on how to advance research and improve treatments for brain disorders.